{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:14:01Z","timestamp":1794539641702,"version":"4.9.1"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T00:00:00Z","timestamp":1724630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012118","name":"Ontario Institute for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012118","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013873","name":"Government of Ontario","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013873","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.eclinm.2024.102824","type":"journal-article","created":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T15:14:59Z","timestamp":1726240499000},"page":"102824","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"C","title":["Frequently asked questions on surrogate endpoints in oncology-opportunities, pitfalls, and the way forward"],"prefix":"10.1016","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0402-1573","authenticated-orcid":false,"given":"Abhenil","family":"Mittal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2042-1262","authenticated-orcid":false,"given":"Myung Sun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9535-525X","authenticated-orcid":false,"given":"Shenna","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7444-8594","authenticated-orcid":false,"given":"Bishal","family":"Gyawali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.eclinm.2024.102824_bib1","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/jamainternmed.2018.8351","article-title":"Estimation of study time reduction using surrogate end points rather than overall survival in oncology clinical trials","volume":"179","author":"Chen","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"Supplement","key":"10.1016\/j.eclinm.2024.102824_bib2","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.4103\/ijc.IJC_1417_20","article-title":"Significance of emerging clinical oncology endpoints in support of overall survival","volume":"59","author":"Patil","year":"2022","journal-title":"Indian J Cancer"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102824_bib3","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/jamaoncol.2021.0379","article-title":"Evolution of the randomized clinical trial in the era of precision oncology","volume":"7","author":"Del Paggio","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eclinm.2024.102824_bib4","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12916-017-0902-9","article-title":"Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?","volume":"15","author":"Kemp","year":"2017","journal-title":"BMC Med"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102824_bib5","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/CCO.0000000000000984","article-title":"Surrogate endpoints for HTA decisions of breast cancer drugs: utility and pitfalls","volume":"35","author":"Wright","year":"2023","journal-title":"Curr Opin Oncol"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102824_bib6","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1001\/jamainternmed.2020.1097","article-title":"FDA acceptance of surrogate end points for cancer drug approval: 1992-2019","volume":"180","author":"Chen","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102824_bib7","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jamainternmed.2015.2829","article-title":"The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses","volume":"175","author":"Prasad","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102824_bib8","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.eclinm.2024.102824_bib9","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1093\/annonc\/mdi373","article-title":"Definition of disease-free survival: this is my truth\u2013show me yours","volume":"16","author":"Chua","year":"2005","journal-title":"Ann Oncol"},{"issue":"27","key":"10.1016\/j.eclinm.2024.102824_bib10","first-page":"3097","article-title":"Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer","volume":"35","author":"Xie","year":"2017","journal-title":"J\u00a0Clin Orthod"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102824_bib11","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/annonc\/mdv106","article-title":"Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)","volume":"26","author":"Gourgou-Bourgade","year":"2015","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102824_bib12","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.ejca.2012.09.035","article-title":"Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials","volume":"49","author":"Bellera","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eclinm.2024.102824_bib13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejca.2020.02.009","article-title":"Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: results of the DATECAN initiative","volume":"130","author":"Cohen","year":"2020","journal-title":"Eur J Cancer"},{"issue":"24","key":"10.1016\/j.eclinm.2024.102824_bib14","first-page":"2720","article-title":"Updated standardized definitions for efficacy end points (STEEP) in adjuvant breast cancer clinical trials: STEEP version 2.0","volume":"39","author":"Tolaney","year":"2021","journal-title":"J\u00a0Clin Orthod"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102824_bib15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/biostatistics\/1.1.49","article-title":"The validation of surrogate endpoints in meta-analyses of randomized experiments","volume":"1","author":"Buyse","year":"2000","journal-title":"Biostatistics"},{"key":"10.1016\/j.eclinm.2024.102824_bib16","series-title":"Institute for quality and efficiency in Health care: executive summaries Institute for Quality and Efficiency in Health Care (IQWiG)","article-title":"Validity of surrogate endpoints in oncology","year":"2011"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102824_bib17","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nrclinonc.2010.43","article-title":"Biomarkers and surrogate end points--the challenge of statistical validation","volume":"7","author":"Buyse","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"issue":"9938","key":"10.1016\/j.eclinm.2024.102824_bib18","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102824_bib19","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1001\/jamaoncol.2015.6113","article-title":"Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: a meta-analysis","volume":"2","author":"Broglio","year":"2016","journal-title":"JAMA Oncol"},{"issue":"15","key":"10.1016\/j.eclinm.2024.102824_bib20","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"34","key":"10.1016\/j.eclinm.2024.102824_bib21","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1200\/JCO.2014.55.2836","article-title":"Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies","volume":"32","author":"Berruti","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.eclinm.2024.102824_bib22","volume":"28","author":"Squifflet","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.eclinm.2024.102824_bib23","article-title":"Association of pathologic complete response and long-term survival outcomes among patients treated with neoadjuvant chemotherapy or chemoradiotherapy for NSCLC: a meta-analysis","volume":"3","author":"Rosner","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.eclinm.2024.102824_bib24","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1200\/PO.21.00108","article-title":"Tumor response end points as surrogates for overall survival in immune checkpoint inhibitor trials: a systematic review and meta-analysis","volume":"5","author":"Kok","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102824_bib25","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.16379","article-title":"Imaging response to contemporary immuno-oncology combination therapies in patients with metastatic renal cell carcinoma","volume":"5","author":"Navani","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102824_bib26","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1186\/s12885-022-10046-z","article-title":"Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings","volume":"22","author":"Hua","year":"2022","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.eclinm.2024.102824_bib27","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/s41416-020-01050-w","article-title":"A\u00a0systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer","volume":"123","author":"Cooper","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eclinm.2024.102824_bib28","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ejca.2018.11.012","article-title":"A\u00a0systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology","volume":"106","author":"Haslam","year":"2019","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102824_bib29","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1186\/s13063-022-06904-7","article-title":"On behalf of the SPIRIT-SURROGATE\/CONSORT-SURROGATE project group. Surrogate endpoints in trials: a call for better reporting","volume":"23","author":"Ciani","year":"2022","journal-title":"Trials"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102824_bib30","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1001\/jamaoncol.2022.5985","article-title":"Use of single-arm trials for US food and drug administration drug approval in oncology, 2002-2021","volume":"9","author":"Agrawal","year":"2023","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102824_bib31","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkab061","article-title":"Feasibility of randomized controlled trials for cancer drugs approved by the food and drug administration based on single-arm studies","volume":"5","author":"Rittberg","year":"2021","journal-title":"JNCI Cancer Spectr"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102824_bib32","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ejca.2011.10.028","article-title":"Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer?","volume":"48","author":"Amir","year":"2012","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.eclinm.2024.102824_bib33","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1002\/cncr.29082","article-title":"Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trials","volume":"121","author":"Matulonis","year":"2015","journal-title":"Cancer"},{"issue":"16","key":"10.1016\/j.eclinm.2024.102824_bib34","first-page":"3717","article-title":"Relationship between progression-free survival and overall survival in randomized clinical trials of targeted and biologic agents in oncology","volume":"10","author":"Hess","year":"2019","journal-title":"J\u00a0Cancer"},{"key":"10.1016\/j.eclinm.2024.102824_bib35","series-title":"Clinical trial endpoints for the approval of cancer drugs and biologics","year":"2018"},{"key":"10.1016\/j.eclinm.2024.102824_bib36","article-title":"Is the number of cancer drug approvals a surrogate for regulatory success?","volume":"22","author":"Gyawali","year":"2019","journal-title":"J\u00a0Cancer Policy"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102824_bib37","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.12454","article-title":"Analysis of supportive evidence for US food and drug administration approvals of novel drugs in 2020","volume":"5","author":"Mitra-Majumdar","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.eclinm.2024.102824_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100332","article-title":"Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs","volume":"21","author":"Gyawali","year":"2020","journal-title":"eClinicalMedicine"},{"issue":"7","key":"10.1016\/j.eclinm.2024.102824_bib39","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamainternmed.2019.0462","article-title":"Assessment of the clinical benefit of cancer drugs receiving accelerated approval","volume":"179","author":"Gyawali","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102824_bib40","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S1470-2045(24)00152-9","article-title":"Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data: a retrospective analysis","volume":"25","author":"Naci","year":"2024","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.eclinm.2024.102824_bib41","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1001\/jama.2024.2396","article-title":"Clinical benefit and regulatory outcomes of cancer drugs receiving accelerated approval","volume":"331","author":"Liu","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102824_bib107","doi-asserted-by":"crossref","first-page":"36","DOI":"10.6004\/jnccn.2019.7345","article-title":"Response rates and durations of response for biomarker-based cancer drugs in nonrandomized versus randomized trials","volume":"18","author":"Gyawali","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"28","key":"10.1016\/j.eclinm.2024.102824_bib108","doi-asserted-by":"crossref","first-page":"6982","DOI":"10.1200\/JCO.2005.06.679","article-title":"Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens","volume":"23","author":"Zia","year":"2005","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.eclinm.2024.102824_bib42","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJM199804303381804","article-title":"Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma","volume":"338","author":"Gleave","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.eclinm.2024.102824_bib43","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1805052","article-title":"Sorafenib for advanced and refractory desmoid tumors","volume":"379","author":"Gounder","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eclinm.2024.102824_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101753","article-title":"Objective response rate of placebo in randomized controlled trials of anticancer medicines","volume":"55","author":"Sachdev","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102824_bib46","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7190","article-title":"An empirical analysis of overall survival in drug approvals by the US FDA (2006-2023)","volume":"13","author":"Elbaz","year":"2024","journal-title":"Cancer Med"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102824_bib47","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.8875","article-title":"Assessment of surrogate end point trends in clinical trials to approve oncology drugs from 2001 to 2020 in Japan","volume":"6","author":"Maeda","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102824_bib48","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.8835","article-title":"Surrogate measures of drug efficacy\u2014a finger pointing at the moon","volume":"6","author":"Avorn","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"32","key":"10.1016\/j.eclinm.2024.102824_bib49","first-page":"4973","article-title":"Regulatory challenges: is a surrogate end point instead of overall survival enough for regulatory approval of (Neo)Adjuvant cancer treatment? The swissmedic perspective","volume":"41","author":"Pavic","year":"2023","journal-title":"J\u00a0Clin Orthod"},{"issue":"13","key":"10.1016\/j.eclinm.2024.102824_bib50","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1016\/j.ejca.2014.05.016","article-title":"Disease-free survival as an end-point in the treatment of solid tumours \u2013 perspectives from clinical trials and clinical practice","volume":"50","author":"Robinson","year":"2014","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102824_bib51","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1470-2045(18)30750-2","article-title":"Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis","volume":"20","author":"Saad","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102824_bib52","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/jnci\/djab187","article-title":"Reevaluating disease-free survival as an endpoint vs overall survival in stage III adjuvant colon cancer trials","volume":"114","author":"Yin","year":"2022","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.eclinm.2024.102824_bib53","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(13)70158-X","article-title":"Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data","volume":"14","author":"Mauguen","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2024.102824_bib54","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1186\/s12885-020-06910-5","article-title":"Disease-free survival as a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a meta-analysis of 20 randomized controlled trials","volume":"20","author":"Nie","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.eclinm.2024.102824_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113977","article-title":"Disease-free survival as a surrogate for overall survival in HR+\/HER2\u2013 early breast cancer: a correlation analysis","volume":"202","author":"Untch","year":"2024","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102824_bib56","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1200\/JCO.20.01762","article-title":"Lessons from ADAURA on adjuvant cancer drug trials: evidence, ethics, and economics","volume":"39","author":"Gyawali","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.eclinm.2024.102824_bib57","first-page":"djad125","article-title":"Evaluating relapse-free survival as an endpoint for overall survival in adjuvant immunotherapy trials","volume":"30","author":"Li","year":"2023","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"13","key":"10.1016\/j.eclinm.2024.102824_bib58","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.20.01204","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial: 6 Years' follow-up","volume":"39","author":"Piccart","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"34","key":"10.1016\/j.eclinm.2024.102824_bib59","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102824_bib60","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Johnston","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2024.102824_bib61","series-title":"FDA D.I.S.C.O. Burst Edition: FDA approval of Verzenio (abemaciclib) with endocrine therapy for patients with HR-positive, HER2-negative, node-positive, early breast cancer","author":"Research C for DE","year":"2023"},{"key":"10.1016\/j.eclinm.2024.102824_bib62","doi-asserted-by":"crossref","first-page":"100730","DOI":"10.1016\/j.eclinm.2021.100730","article-title":"A\u00a0correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer","volume":"32","author":"Gyawali","year":"2021","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.eclinm.2024.102824_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.07.221","article-title":"186P Evaluation of event-free survival as a surrogate for overall survival in early-stage triple-negative breast cancer following neoadjuvant therapy","volume":"33","author":"Fasching","year":"2022","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102824_bib64","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10549-020-05615-4","article-title":"Meta-analyses on progression-free survival as a surrogate endpoint for overall survival in triple-negative breast cancer","volume":"181","author":"Hirai","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102824_bib66","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12916-023-02754-5","article-title":"Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database","volume":"21","author":"Courtinard","year":"2023","journal-title":"BMC Med"},{"issue":"33","key":"10.1016\/j.eclinm.2024.102824_bib67","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1200\/JCO.2007.11.8836","article-title":"Progression-free survival is a surrogate for survival in advanced colorectal cancer","volume":"25","author":"Buyse","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.eclinm.2024.102824_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.672916","article-title":"Correlation between early endpoints and overall survival in non-small-cell lung cancer: a trial-level meta-analysis","volume":"11","author":"Shameer","year":"2021","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.eclinm.2024.102824_bib69","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1200\/JCO.2014.59.0489","article-title":"Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses","volume":"33","author":"Blumenthal","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102824_bib70","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.18939","article-title":"Assessment of progression-free survival as a surrogate end point of overall survival in first-line treatment of ovarian cancer: a systematic review and meta-analysis","volume":"3","author":"Paoletti","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102824_bib71","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.0416","article-title":"A\u00a0comparison of response patterns for progression-free survival and overall survival following treatment for cancer with PD-1 inhibitors: a meta-analysis of correlation and differences in effect sizes","volume":"1","author":"Gyawali","year":"2018","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.eclinm.2024.102824_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102156","article-title":"Intermediate endpoints as surrogates for outcomes in cancer immunotherapy: a systematic review and meta-analysis of phase 3 trials","volume":"63","author":"Zhang","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.eclinm.2024.102824_bib73","doi-asserted-by":"crossref","first-page":"102542","DOI":"10.1016\/j.ctrv.2023.102542","article-title":"Comprehensive evaluation of surrogate endpoints to predict overall survival in trials with PD1\/PD-L1 immune checkpoint inhibitors plus chemotherapy","volume":"116","author":"G","year":"2023","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102824_bib74","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1470-2045(24)00040-8","article-title":"Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled analysis","volume":"25","author":"Goulart","year":"2024","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.eclinm.2024.102824_bib75","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1343774","article-title":"Alternative metrics for assessing clinical benefit with immunotherapy in oncology","volume":"8","author":"Chan","year":"2018","journal-title":"Oncoimmunology"},{"issue":"11","key":"10.1016\/j.eclinm.2024.102824_bib76","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/s41416-020-0805-y","article-title":"Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review","volume":"122","author":"Belin","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eclinm.2024.102824_bib77","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.eclinm.2024.102824_bib78","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/s41571-023-00805-7","article-title":"Problematic crossovers in cancer drug trials","volume":"20","author":"Gyawali","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102824_bib79","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ejca.2014.12.016","article-title":"Influence of censoring on conclusions of trials for women with metastatic breast cancer","volume":"51","author":"Templeton","year":"2015","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102824_bib80","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-020-0368-0","article-title":"Informative censoring \u2014 a neglected cause of bias in oncology trials","volume":"17","author":"Templeton","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102824_bib81","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1001\/jamaoncol.2021.8206","article-title":"Biased evaluation in cancer drug trials-how use of progression-free survival as the primary end point can mislead","volume":"8","author":"Tannock","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eclinm.2024.102824_bib82","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2021.04.044","article-title":"Informative censoring of surrogate end-point data in phase 3 oncology trials","volume":"153","author":"Gilboa","year":"2021","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.eclinm.2024.102824_bib83","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1093\/annonc\/mdu456","article-title":"Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2\u2020","volume":"25","author":"Piccart","year":"2014","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102824_bib84","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor\u2013positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.eclinm.2024.102824_bib85","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1200\/JCO.2006.09.6198","article-title":"Proposal for the use of progression-free survival in unblinded randomized trials","volume":"25","author":"Freidlin","year":"2007","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.eclinm.2024.102824_bib109","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1200\/JCO.23.01423","article-title":"Progression-free survival should not be used as a primary end point for registration of anticancer drugs","volume":"41","author":"Booth","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102824_bib86","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/jamaoncol.2019.0167","article-title":"Analysis of control arm quality in randomized clinical trials leading to anticancer drug approval by the US food and drug administration","volume":"5","author":"Hilal","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eclinm.2024.102824_bib87","doi-asserted-by":"crossref","first-page":"112920","DOI":"10.1016\/j.ejca.2023.05.008","article-title":"Analysis of the adequacy of control arms in oncology randomized clinical trials published between 2017 and 2021: a meta-research study","volume":"189","author":"Rossi","year":"2023","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.eclinm.2024.102824_bib110","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41571-021-00504-1","article-title":"FDA approval standards for anticancer agents - lessons from two recent approvals in breast cancer","volume":"18","author":"Gyawali","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102824_bib88","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1634\/theoncologist.2009-0261","article-title":"Blinded independent central review of the progression-free survival endpoint","volume":"15","author":"Amit","year":"2010","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102824_bib89","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/annonc\/mdy514","article-title":"Exaggeration of PFS by blinded, independent, central review (BICR)","volume":"30","author":"Stone","year":"2019","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.eclinm.2024.102824_bib90","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1002\/ijc.31957","article-title":"Association between progression-free survival and patients' quality of life in cancer clinical trials","volume":"144","author":"Hwang","year":"2019","journal-title":"Int J Cancer"},{"issue":"12","key":"10.1016\/j.eclinm.2024.102824_bib91","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1001\/jamainternmed.2018.4710","article-title":"Evaluating progression-free survival as a surrogate outcome for health-related quality of life in oncology: a systematic review and quantitative analysis","volume":"178","author":"Kovic","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102824_bib92","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1001\/jamaoncol.2022.0864","article-title":"Association of quality-of-life outcomes in cancer drug trials with survival outcomes and drug class","volume":"8","author":"Samuel","year":"2022","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.eclinm.2024.102824_bib93","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1093\/oncolo\/oyad064","article-title":"Patient understanding of oncology clinical trial endpoints in direct-to-consumer television advertising","volume":"28","author":"Sullivan","year":"2023","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102824_bib94","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S1470-2045(22)00015-8","article-title":"Progression-free survival: it is time for a new name","volume":"23","author":"Gyawali","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2024.102824_bib95","article-title":"Patients' attitudes and preferences toward delayed disease progression in the absence of improved survival","volume":"17","author":"Brundage","year":"2023","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102824_bib96","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1200\/JCO.21.02937","article-title":"Margetuximab versus trastuzumab in patients with previously treated HER2-positive advanced breast cancer (SOPHIA): final overall survival results from a randomized phase 3 trial","volume":"41","author":"Rugo","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102824_bib97","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jamaoncol.2020.7932","article-title":"Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial","volume":"7","author":"Rugo","year":"2021","journal-title":"JAMA Oncol"},{"issue":"27","key":"10.1016\/j.eclinm.2024.102824_bib98","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1200\/JCO.20.00147","article-title":"Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with \u2265 2 HER2-directed regimens: phase III NALA trial","volume":"38","author":"Saura","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102824_bib99","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/jnci\/djz211","article-title":"A\u00a0systematic review and meta-analysis of bevacizumab in first-line metastatic breast cancer: lessons for research and regulatory enterprises","volume":"112","author":"Hey","year":"2019","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.eclinm.2024.102824_bib100","series-title":"Clinical trial considerations to support accelerated approval of oncology therapeutics","year":"2023"},{"issue":"11","key":"10.1016\/j.eclinm.2024.102824_bib101","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1056\/NEJMp2306872","article-title":"The accelerated approval program for cancer drugs - finding the right balance","volume":"389","author":"Gyawali","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.eclinm.2024.102824_bib102","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nrclinonc.2017.72","article-title":"Combining drugs and extending treatment - a PFS end point is not sufficient","volume":"14","author":"Gyawali","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102824_bib103","doi-asserted-by":"crossref","first-page":"100117","DOI":"10.1016\/j.esmoop.2021.100117","article-title":"Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring","volume":"6","author":"Gyawali","year":"2021","journal-title":"ESMO Open"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024004036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024004036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T19:09:04Z","timestamp":1732043344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537024004036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":105,"alternative-id":["S2589537024004036"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102824","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Frequently asked questions on surrogate endpoints in oncology-opportunities, pitfalls, and the way forward","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102824","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102824"}}